Genital Psoriasis Guidance Recommends Routine Assessment and Age-Specific Treatments for 60% Affected Patients
ARQT•Arcutis Biotherapeutics’ Genital Psoriasis Wellness Consortium published age-specific clinical guidance covering pediatric, adult and older patients, emphasizing routine genital assessment, empathetic communication and age-tailored treatments. Guidance, developed via a modified Delphi with ≥75% expert agreement, highlights that genital involvement affects over 60% of US psoriasis patients.
1. Publication of Age-Specific Guidance
Arcutis Biotherapeutics’ Genital Psoriasis Wellness Consortium released its second consensus manuscript, offering healthcare providers detailed, age-specific recommendations for diagnosing and managing genital psoriasis across pediatric, adult and older patient groups.
2. Consensus Development Methodology
The guidance emerged from a modified Delphi process involving multidisciplinary U.S.-based clinicians, applying a consensus threshold of at least 75% agreement on a seven-point Likert scale to validate each recommendation.
3. Core Clinical Recommendations
Practitioners are advised to integrate routine genital exams into standard skin assessments, use stigma-reducing communication, offer chaperones for minors, and customize treatments by age while minimizing long-term topical corticosteroids and considering non-steroidal options.
4. Prevalence and Impact
Genital involvement occurs in approximately two-thirds of the nine million U.S. plaque psoriasis patients; these guidelines aim to improve early recognition, patient engagement and personalized care for this under-recognized condition.
